TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01189604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of placebo, same infusion rates as for arm 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICI35,868 (propofol)
Description: Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICI35,868 (propofol)
Description: Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICI35,868 (propofol)
Description: Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICI35,868 (propofol)
Description: Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICI35,868 (propofol)
Description: Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICI35,868 (propofol)
Description: Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
Study: NCT02100514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615; RN316)
Description: 150 mg every 2 weeks, subcutaneous injection for 52 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection every 2 weeks for 52 weeks.
Study: NCT03021941

Intervention type: DRUG
Group type: OTHER
Intervention: Elelyso 60 units/kg
Description: All patients receive Elelyso 60 units/kg.
Study: NCT02329912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartPill
Description: Application of the SmartPill at the end of surgery

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SmartPill
Description: Application of the SmartPill at the end of surgery
Study: NCT03617497

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: scalp EEG and polysomnography
Description: 48 hour 22 channel EEG with polysomnography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: scalp EEG and polysomnography
Description: 48 hour 22 channel EEG with polysomnography

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: scalp EEG and polysomnography
Description: 48 hour 22 channel EEG with polysomnography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: scalp EEG with foramen ovale electrodes with polysomnography
Description: long-term scalp EEG with additional foramen ovale electrodes with polysomnography
Study: NCT01951274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPD-737
Description: NK1 Receptor Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPD-737
Description: NK1 Receptor Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPD-737
Description: NK1 Receptor Antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02483403

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study: NCT02569658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02354495

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Changes in energy and protein intake
Description: Energy intake will be based on accurate measurements of energy expenditure. Protein intake will be matched to age-based recommended values if necessary.
Study: NCT02631759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lévétiracetam
Description: Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of placebo 250 mg every 24 hours (evening).
Study: NCT03703622

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video-debriefing with standard HBB training compared with standard HBB training only
Description: We will use the AAP training curriculum for the HBB 2nd edition through out the training and course assessments pre-and post- training and during follow-up period.~Both intervention arms will a 2 days training consisting of: lectures, neonatal resuscitation demonstrations using NeoNatali mannequin, and practical skills s sessions. Pre- and post-tests knowledge (MCQs) and skills (bag mask ventilation, OSCE A, \& OSCE B) will be given to all participants.~In the intervention arm, in addition to standard training, participants will work in teams of three (birth attendant, mother, and an assistant) to perform different HBB case scenarios. These will be filmed and used for subsequent debriefing after each case scenarios. After all participants in the intervention have had the opportunity to participate in the debriefing, then a post test is done to assess performance.~Analysis is done to compare the intervention and control arms performances.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-debriefing with standard HBB training compared with standard HBB training only
Description: We will use the AAP training curriculum for the HBB 2nd edition through out the training and course assessments pre-and post- training and during follow-up period.~Both intervention arms will a 2 days training consisting of: lectures, neonatal resuscitation demonstrations using NeoNatali mannequin, and practical skills s sessions. Pre- and post-tests knowledge (MCQs) and skills (bag mask ventilation, OSCE A, \& OSCE B) will be given to all participants.~In the intervention arm, in addition to standard training, participants will work in teams of three (birth attendant, mother, and an assistant) to perform different HBB case scenarios. These will be filmed and used for subsequent debriefing after each case scenarios. After all participants in the intervention have had the opportunity to participate in the debriefing, then a post test is done to assess performance.~Analysis is done to compare the intervention and control arms performances.
Study: NCT00180544

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenting: Renal Artery
Description: Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
Study: NCT03326544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saphenous nerve block group
Description: Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma group
Description: Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
Study: NCT01488370

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation
Study: NCT03681431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 4g/ 24h
Description: Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone 2g/ 12h
Description: Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
Study: NCT01628133

Intervention type: PROCEDURE
Intervention: ultrasound
Description: sonographic evaluation of intestinal blood flow
Study: NCT03128567

Intervention type: DEVICE
Intervention: Stimulation of the subthalamic nucleus
Description: Stimulation of the subthalamic nucleus
Study: NCT03236025

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Video+brief smoking cessation+pamphlet
Description: The videos presented the health effects of smoking, especially emphasizing the importance of smoking cessation on pregnant women, fetuses, and newborns.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Text-message+brief smoking cessation+pamphlet
Description: The text -message contains the same content with the videos

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: brief smoking cessation+pamphlet
Description: The pamphlet showed the general information related to the smoking cessation, the brief smoking cessation only contains a sentence like You'd better quit smoking.
Study: NCT03531697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Loteprednol Etabonate
Description: Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic Loteprednol Etabonate
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Listed Drug (RLD)
Description: Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Listed Drug (RLD)
Description: Drug
Study: NCT02785120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TF0023
Description: TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TF0023
Description: TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TF0023
Description: TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
Study: NCT02038881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE®
Description: 0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE®
Description: 0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE®
Description: 0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
Study: NCT03795454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing
Description: Infant-directed singing and singing of self-invented songs, especially songs emerging from the interaction with the infant, are especially encouraged. The families will receive audio material of children's songs, lullabies, and lyrics of the lullabies to support them if they feel unable to accomplish the task otherwise.
Study: NCT03166007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: The participant should be supine and in a relaxed atmosphere, though this may depend on level of disability. The massage comprises 4 basic strokes (10minutes); Stroking from the small of the back over the iliac crest and down both sides of the pelvis towards the groin; Effleurage follows the direction of the ascending colon across the transverse colon and down the descending colon. This is repeated several times with increasing pressure; Palmar kneading tracks down the descending colon up the ascending colon and down the descending colon once again. Effleurage is repeated and continued with a relaxing transverse stroke over the abdomen; Vibration over the abdominal wall to relieve flatus concludes the massage session. The participants in this group will receive one telephone call per week for 6 weeks and again at 24 weeks to further discuss their bowel management.
Study: NCT03811574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
Study: NCT01274299

Intervention type: PROCEDURE
Intervention: Digital camera picture
Description: A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.
Study: NCT04213053

Intervention type: PROCEDURE
Group type: OTHER
Intervention: strabismus surgery
Description: Lees screen before and after concomitant strabismus surgery
Study: NCT03294668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KONTAKT Australia
Description: KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Super Chef
Description: The Super Chef is a cooking group designed for this study for adolescents on the Autism Spectrum, aimed at teaching basic cooking skills in a social environment. The Super Chef participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
Study: NCT01970930

Intervention type: PROCEDURE
Intervention: Blood specimen
Description: 4 green top tube 40 cc of blood draw
Study: NCT04785079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Graston Instrument assisted Soft tissue Mobilization
Description: Instrument assisted soft tissue mobilization using the Graston tool and technique for 3 minutes on each of the three locations
Study: NCT01935362

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citrus supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00603434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS-MPH
Description: 18 mg bid on days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS-MPH
Description: 27mg bid on days 3 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS-MPH
Description: 35 mg bid on days 5-9
Study: NCT00622869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (reduced tacrolimus)
Description: After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (tacrolimus elimination)
Description: After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (tacrolimus control)
Description: Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
Study: NCT04319874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum
Description: Participants take ganoderma lucidum spore powder once a day, 1000mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Subjects are treated with conventional chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Subjects are treated with conventional chemotherapy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Chemotherapy
Description: Subjects are treated with conventional chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects are treated with conventional chemotherapy and Placebos once a day, 1000mg
Study: NCT01832480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTZ 500 mg twice daily x 7 days
Description: MTZ 500 mg twice daily x 7 days
Study: NCT03769350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered CBT for MDD
Description: 8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
Study: NCT00622869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (reduced tacrolimus)
Description: Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (tacrolimus elimination)
Description: Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
Study: NCT02973321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Orally administered at a stable dose , \>=1500 mg daily stable dose or maximal tolerated dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Orally administered at a stable dose , \>=1500 mg daily stable dose or maximal tolerated dose.
Study: NCT00519493

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clozex
Description: One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
Study: NCT04628728

Intervention type: OTHER
Intervention: Survey based on questionnaire (self-designed)
Description: Participants are handed a questionnaire to asses comprehension of medical content provided in the referral letters.

Intervention type: OTHER
Intervention: Survey based on questionnaire (self-designed)
Description: Participants are handed a questionnaire to asses comprehension of medical content provided in the referral letters.